Matthew Abrams, MD

Husband | Father | GI Radiation Oncologist at @BIDMChealth | @Harvardmed | Gastrointestinal Oncology Program | #MedEd | #RadOnc | Tweets my own

[Matthew Abrams, MD @abrams_md]

Rad onc + radiology like peas and carrots 🟢 🥕

[Shanna Matalon, MD @ShannaMatalonMD]

special guest at our abdominal imaging & intervention fellowship morning conference today...@abrams_md!!!

#radiology + #radiationoncology go together like peanut butter + jelly! one of my favorite parts of my job is working with our rad onc colleagues.

[Jason Beckta @drbeckta]

@radioactivered Well, the most interesting thing about the Radium Girls is actually how few of them got cancer.

"Only" 56 out of 1,468. I would argue that was, you know, 56 too many because it was entirely preventable, but still.

It's actually a great example of...wait for it...a threshold...

[Drew Moghanaki @DrewMoghanaki]

Controversial statement by @SJFrankMD, informed by the ProtecT study results, for those who still think prostatectomy is the better treatment. #ASTRO26

[Jeff Ryckman @jryckman3]

Really interesting randomized data from #ASTRO26.

Wang et al. randomized 93 patients with solitary HCC ≤2 cm, all suitable for either treatment, to RFA vs SBRT 50 Gy/5 fx.

2-year LPFS:
• RFA: 87.0%
• SBRT: 91.5%
• Difference +4.5%, meeting noninferiority

2-year OS was ~98% in both arms, with similar acute toxicity.

Small, single-center interim trial with a wide CI, so I would not overinterpret it. But this is another prospective randomized data point supporting SBRT as a legitimate definitive ablative option for small HCC, not simply a fallback when RFA (or other invasive interventions) cannot be performed.

#OncTwitter @NiuSanford @KrishanJethwa @nbn426

[Dr. Nina Niu Sanford @NiuSanford]

GI003 HCC proton vs photon: no dif OS, PFS, Gr 3+ AEs.

Protons = 1 option in expanding RT toolbox (MRgRT, adaptive, etc) to optimize therapeutic ratio, & each case should be individualized by tumor & liver fxn.

But w neg RCT & $/access dif, photon RT should remain SOC. #ASTRO26

[Erman Akkus @Erman_Akkus]

Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial

https://t.co/KQlw5yNMeF

[Drew Moghanaki @DrewMoghanaki]

A randomized trial confirms that visceral reactions matter when the word "radiation" is used as an adjective to describe a cancer therapy. Following this publication, I have adopted the preferred European terminology by using the term "Radiotherapy" in all of my sentences with my patients.

Try it out. You might like it too!

https://t.co/p8z1NA0NgO

[Jason Beckta @drbeckta]

I love the hidden gems in CMS datasets.

Which one of you ABSOLUTE ANIMALS tried to bill SBRT for LDRT in 2024??

Normally I'd assume it was a coding error, but given this is in the appeals claims...it means someone actually tried to do it.

Intentionally.

[Ralph Weichselbaum @rweichselbaum]

@LiangChengMD You don’t sound incredibly humbled

[Pimul Sarikh @PimulSarikh]

@jryckman3 Credentialism / focus on someone's SCOPUS profile is textbook definition of ad hominem. Only here for the meta-debate, carry on with the science debate 😀

[Jay Detsky @jaydetsky]

Claude's conclusion on the subject /end

[Bruno Bockorny MD @BrunoBockorny]

Presented Phase 1 denikitug at #AACR26. Anti-CCR8 mAb is pharmacologically active at ≥10 mg: CCR8+ intratumoral Treg depletion and Teff activation on paired biopsies. Antitumor responses in heavily pretreated pts, including anti-PD-(L)1 refractory. Manageable safety. Supports mono and combo development. @BIDMC_CancerCtr @DanaFarber

[Jason Beckta @drbeckta]

"Began ~2.5 months ago"
"Recently completed"

79.2Gy in 44 fractions: BASED.

His RadOnc clearly understands how to choose wisely.

[Matthew Abrams, MD @abrams_md]

@aiims2738 That’s my department!

[Matthew Abrams, MD @abrams_md]

@NiuSanford @rweichselbaum @ACRORadOnc @RadoncROVER Me too please

[Matthew Abrams, MD @abrams_md]

@olsonplanner Start doing a backdoor roth IRA right away, and do it every year

[Matthew Abrams, MD @abrams_md]

@olsonplanner Lot of truths to all of this

[Matthew Abrams, MD @abrams_md]

@olsonplanner Look for other jobs and see what they are offering

[Matthew Abrams, MD @abrams_md]

@jryckman3 Hope that comes with a healthy pay raise

[Krishan Jethwa @KrishanJethwa]

🚨SPRING-01🚨

🔍Locally Advanced Rectal Cancer

RCT:
25 Gy x 5 ➡️ CAPOX +- Sintilimab

🔥+ Sintilimab demonstrated:

✅⬆️pCR 59% vs 33%
✅No significant adverse surgical or safety signals

Time to explore with organ preserving approaches⁉️

#ASCO25

[Matthew Abrams, MD @abrams_md]

@NiuSanford ctDNA is the classic scenario of make a product then determine its usefulness. All it does is provide anxiety to patients